WAT241115C350000
- 9.70
- -28.40-74.54%
Waters Newsroom
Jefferies Maintains Waters(WAT.US) With Buy Rating, Raises Target Price to $700
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Maintains Target Price $410
Wells Fargo Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415
Waters Corp Is Maintained at Underweight by Barclays
Waters Analyst Ratings
Stifel Nicolaus Remains a Hold on Waters (WAT)
Leerink Partners Adjusts Price Target on Waters to $400 From $375, Maintains Outperform Rating
Wells Fargo Maintains Waters(WAT.US) With Buy Rating, Raises Target Price to $415
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $360
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Raises Target Price to $410
Deutsche Bank Adjusts Price Target on Waters to $325 From $310
Bernstein Adjusts Waters Price Target to $345 From $315, Maintains Market Perform Rating
Barclays Maintains Waters(WAT.US) With Sell Rating, Maintains Target Price $330
Waters Corp Is Maintained at Underweight by Barclays
Waters Analyst Ratings
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $330
Jefferies Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415
Upgrading Waters: A Buy Rating on LC Replacement Cycle and Strong Sector Positioning
Jefferies Maintains Waters(WAT.US) With Buy Rating, Maintains Target Price $415